并非所有CBD健康宣称都受到同等对待
If you read this blog and keep a close eye on the cannabidiol (“CBD”) industry, you know that the Federal Trade Commission (“FTC”) takes issue with advertising tools containing egregious, unfounded claims about the health benefits of CBD products. Yet, you might be surprised to read that the federal agency does not go after every
《公平劳动标准法》是否适用于大麻企业？美国最高法院或将作出裁决
Cannabis isn’t federally legal. Companies who operate in the cannabis space really only have the protection of the state’s laws in which they operate. Even full compliance with state laws is no shield to federal penalties or enforcement. Also, there is always a risk that cannabis contracts may not be upheld in court because they
销售CBD产品？美国最高法院刚刚提高了商标主张的门槛
几个月前，我曾撰写过一篇关于CBD及《兰哈姆法》下虚假广告的文章，并提到了美国最高法院审理的一起涉及商标案件损害赔偿的重要案件——Romag Fasteners, Inc. 诉 Fossil, Inc. 案（最高法院案号 18-1233）。您可能还记得，《兰哈姆法》又称
CBD相关指控：联邦执法行动不再仅限于警告信
随着新冠肺炎（COVID-19）疫情的蔓延，大麻二酚（CBD）的在线销售量激增，其中包括源自大麻的CBD产品。令人遗憾的是，在当前充满不确定性的时期，少数CBD企业正利用人们对病毒传播的恐惧与焦虑，宣称CBD能够治疗甚至治愈新冠肺炎。
大麻专利持有者UCANN申请破产。此举能否奏效？
总部位于科罗拉多州的联合大麻公司（United Cannabis Corporation，简称UCANN）于4月22日申请第11章破产保护。常读本刊的读者或许记得，UCANN正是首例大麻专利保护诉讼的原告方，该案主要涉及纯度超过95%的CBD和/或THC的液态大麻素制剂。目前该诉讼已因此暂停。
国际大麻产业持续瞄准美国市场
尽管新冠疫情导致全球许多地区放缓了步伐，但许多行业的商业交易仍在继续。随着企业进军新的国际市场，或试图将部分业务或供应链从中国等高风险市场转移至东南亚等低风险市场，它们仍在积极寻求战略性收购、合作伙伴关系和投资机会。
大麻、冠状病毒与联邦灾难援助
新冠疫情对大麻销售大有裨益。在大多数已批准大麻项目的州，无论是医疗用大麻还是成人娱乐用大麻的销售，均被州和地方政府列为“必要服务”。得益于这一支持，大麻行业的供应链在应对新冠疫情方面表现得比许多其他行业更为从容。尽管如此，疫情仍在持续蔓延，大麻企业正面临
合成CBD是否合法？
Although the enactment of the 2018 Farm Bill legalized hemp, the production of the plant and its derivatives – or certain aspects of it – remain prohibited in some states. As a result, many stakeholders are contemplating the idea of using synthetic CBD over its naturally derived counterpart. But does the lack of hemp and
丝芙兰引领CBD化妆品监管新风尚
While the U.S. Food and Drug Administration (“FDA”) continues to drag its feet in forging a clear path for the sale and marketing of hemp-derived cannabidiol (“Hemp CBD”) products, foreign agencies and industry players are leading the way by adopting their own sets of regulations. Last week, giant beauty retailer Sephora announced it was now